Trials / Completed
CompletedNCT00879905
A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors
A Phase I Dose Escalation, Multi-center, Open-label Study of HSP990 Administered Orally in Adult Patients With Advanced Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will study the safety, tolerability and metabolism of a drug called HSP990 when given by mouth once a week or twice weekly to subjects with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HSP990 |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2012-07-01
- Completion
- 2012-07-01
- First posted
- 2009-04-13
- Last updated
- 2020-12-08
Locations
3 sites across 3 countries: Canada, France, Spain
Source: ClinicalTrials.gov record NCT00879905. Inclusion in this directory is not an endorsement.